Comparative Effectiveness of Team-Based Care with a Clinical Decision Support System Versus Team-Based Care Alone on Cardiovascular Risk Reduction among Patients with Diabetes: Rationale and Design of the D4C Trial.
Xiulin Shi,Jiang He,Mingzhu Lin,Changqin Liu,Bing Yan,Haiqu Song,Caihong Wang,Fangsen Xiao,Peiying Huang,Liying Wang,Zhibin Li,Yinxiang Huang,Mulin Zhang,Chung-Shiuan Chen,Katherine Obst,Weihua Li,Shuyu Yang,Guanhua Yao,Xuejun Li
DOI: https://doi.org/10.1016/j.ahj.2021.04.009
IF: 5.099
2021-01-01
American Heart Journal
Abstract:Background Diabetes has become a major public health challenge worldwide, especially in low- and middle-income countries (LMICs). Uncontrolled hyperglycemia, hypertension, and dyslipidemia - major risk factors for all-cause mortality and cardiovascular disease (CVD) - are common in patients with diabetes in China. We propose to compare the effectiveness of team-based care plus a clinical decision support system (CDSS) with team-based care alone on glycemic, blood pressure (BP), and lipid control, and clinical CVD reduction among patients with type-2 diabetes and at high risk for CVD. Methods The Diabetes Complication Control in Community Clinics (D4C) study is a cluster-randomized trial conducted among 38 community health centers in Xiamen City, China. Nineteen clinics have been randomly assigned to team-based care plus CDSS and 19 to team-based care alone. Team-based care includes primary care providers, health coaches, and diabetes specialists working collaboratively with patients to achieve shared treatment goals for CVD risk factor reduction. The CDSS integrates guideline-based treatment algorithms for glycemic, BP, and lipid control, along with a patient's medical history and insurance policy, to recommend treatment and follow-up plans. In phase 1, the co-primary outcomes are mean reduction in glycated hemoglobin (HbA1c), systolic BP (SBP), and low-density lipoprotein (LDL)-cholesterol over 18 months, and the proportion of patients with controlled HbA1c, SBP, and LDL-cholesterol at 18 months' between the 2 comparison groups. In phase 2, the primary outcome is the difference in major CVD incidence (non-fatal stroke, non-fatal myocardial infarction, hospitalized heart failure, and CVD mortality) between the 2 comparison groups. Mean reduction in HbA1c, SBP, and LDL-cholesterol levels will be simultaneously modeled for a single overall treatment effect. Conclusion The D4C trial will generate evidence on whether a CDSS will further reduce the CVD burden among patients with diabetes beyond team-based care at community clinics. If proven effective, this implementation strategy could be scaled up within primary care settings in China and other LMICs to reduce CVD incidence and mortality among patients with diabetes.